Access to pharmaceutical products in six European countries – analysis of different pharmaceutical distribution systems | Zendy

E. Walter | Zendy; A. Dragosits | Zendy; M. Said | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Access to pharmaceutical products in six European countries – analysis of different pharmaceutical distribution systems

Author(s) -

E. Walter,

A. Dragosits,

M. Said

Publication year - 2012

Publication title -

farmeconomia health economics and therapeutic pathways

Language(s) - English

Resource type - Journals

eISSN - 1721-6923

pISSN - 1721-6915

DOI - 10.7175/fe.v13i1.192

Subject(s) - pharmacy , business , distribution (mathematics) , pharmaceutical industry , pharmaceutical policy , cash , marketing , access to medicines , health care , finance , economics , medicine , developing country , health policy , family medicine , economic growth , pharmacology , mathematical analysis , mathematics

OBJECTIVES: The aim of the study was to draw a comprehensive picture of the pharmaceutical wholesale sector, outlining its socio-economic importance compared to different distribution systems such as short-line wholesaling, direct sales from manufacturers, Reduced Wholesale Arrangements (RWA) and Direct to Pharmacy (DTP) arrangements. Its role is considered from an economic, effectiveness and, most importantly, a public health viewpoint with qualitative and quantitative methods, focusing on France, Germany, Italy, the Netherlands, Spain and the UK. METHODS: First, data has been sourced from annual GIRP and IMS-Health statistics; second, a systematic literature research verified the empirical findings; third, an online-questionnaire was directed to pharmacies. Further data have been sourced from a questionnaire, addressing GIRP-full-member associations and wholesale companies (return rate 86%). RESULTS: On a weighted average, pharmaceutical full-line wholesalers in the observed countries alone pre-finance € 10.2 bn over a period of 41 days the entire medicine-market and secure the cash-flow of the social-insurers (Germany: € 2.60 bn for 38 days; Italy: € 2.27 bn for 68 days; the UK: € 1.48 bn for 36 days; France: € 1.28 bn for 22 days; Spain: € 969.76 m for 27 days; the Netherlands: € 399.09 m for 30 days on average). On average, pharmaceutical full-line wholesalers are bundling products of 18.28 manufacturers per delivery. The process costs would increase by € 164,922.43 to € 171,510.06 per year, if there were no pharmaceutical full-line wholesalers. These additional costs would have to be paid by manufacturers, pharmacies and finally by patients. Regarding the satisfaction with different distribution models, the results of the online-questionnaire show that pharmacists in the observed countries are very satisfied with the distribution through their pharmaceutical full-line wholesalers. CONCLUSIONS: The study showed that pharmaceutical full-line wholesalers have an important and unique position in the pharmaceutical supply chain. Special functions like the pre-financing of the entire medicinal product market, or the guarantee of the continuous supply of all medicinal products verify these findings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research